Indication
High-risk neuroblastoma
High-risk neuroblastoma is an aggressive clinical subset of neuroblastoma, an extracranial solid tumor of primitive neural crest cells that typically arises in the adrenal medulla or sympathetic ganglia. Read more about High-risk neuroblastoma
2 drugs 2 manufacturers
Drugs that treat it
Common High-risk neuroblastoma therapies.
IWILFIN (eflornithine HCl)
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonHigh-risk neuroblastoma is an aggressive clinical subset of neuroblastoma, an extracranial solid tumor of primitive neural crest cells that typically arises in the adrenal medulla or sympathetic ganglia.
Primarily affecting infants and young children, this categorization encompasses patients with metastatic dissemination diagnosed at or after 18 months of age, or localized disease characterized by high-risk biological features regardless of age.
Its defining pathophysiologic hallmarks include unfavorable tumor histopathology and distinct cytogenetic abnormalities, most notably *MYCN* oncogene amplification and recurrent segmental chromosomal alterations, which drive rapid disease progression, treatment resistance, and high rates of recurrence.
- nih.gov
High-risk neuroblastoma is an aggressive clinical subset of neuroblastoma, an extracranial solid tumor of primitive neural crest cells that typically arises in the adrenal medulla or sympathetic ganglia Its defining pathophysiologic hallmarks include unfavorable tumor histopathology and distinct cytogenetic abnormalities, most notably *MYCN* oncogene amplification and recurrent segmental chromosomal alterations, which drive rapid disease progression, treatment resistance, and high rates of recur...
- nih.gov
High-risk neuroblastoma is an aggressive clinical subset of neuroblastoma, an extracranial solid tumor of primitive neural crest cells that typically arises in the adrenal medulla or sympathetic ganglia Primarily affecting infants and young children, this categorization encompasses patients with metastatic dissemination diagnosed at or after 18 months of age, or localized disease characterized by high-risk biological features regardless of age
- nih.gov
Its defining pathophysiologic hallmarks include unfavorable tumor histopathology and distinct cytogenetic abnormalities, most notably *MYCN* oncogene amplification and recurrent segmental chromosomal alterations, which drive rapid disease progression, treatment resistance, and high rates of recurrence
Personalize your experience
Follow High-risk neuroblastoma and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.